Silexion Therapeutics (NASDAQ: SLXN) has completed data collection for its first study of SIL-204 in orthotopic pancreatic cancer models. This study examined the drug’s ability to shrink primary tumors and limit metastasis after systemic administration. The company expects to release initial results in March 2025.
This study is important because orthotopic models, where tumor cells are implanted directly into the pancreas, offer a more accurate representation of human pancreatic cancer than traditional subcutaneous models. This allows researchers to better understand how a drug might perform in a clinically relevant setting, particularly regarding metastatic spread, a hallmark of pancreatic cancer. The evaluation of SIL-204 in this context could significantly impact the development of new therapies, potentially leading to more effective treatments.
This study represents the first time SIL-204 has been systematically evaluated in orthotopic pancreatic cancer models after subcutaneous administration. It focused on the drug’s impact on both primary tumor growth and the spread of the cancer to other organs. The data analysis is currently underway.
The results of this study will directly influence Silexion’s development strategy for SIL-204. Positive data could accelerate the drug’s clinical development and potentially broaden its application to include both localized and metastatic pancreatic cancer, representing a significant advancement in the treatment of this challenging disease. This could also position Silexion as a leader in the development of RNAi therapies for KRAS-driven cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
